Rezolute
Specializing in the development of drug therapies for patients with metabolic and orphan diseases.
Launch date
Employees
Market cap
€264m
Enterprise valuation
€194m (Public information from Sep 2024)
Share price
$4.82 RZLT
Louisville Kentucky (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | 16.4m | 22.7m |
% growth | - | - | - | - | - | - | 38 % |
EBITDA | (20.3m) | (22.3m) | (41.5m) | (51.8m) | - | - | - |
Profit | (20.3m) | (20.9m) | (41.1m) | (51.8m) | (63.0m) | (57.3m) | (72.7m) |
% profit margin | - | - | - | - | - | (349 %) | (320 %) |
EV / revenue | - | - | - | - | - | 11.9x | 8.0x |
EV / EBITDA | -1.3x | -5.3x | -2.6x | -1.4x | - | - | - |
R&D budget | 14.5m | 15.0m | 32.5m | 43.8m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$30.0m | Post IPO Debt | ||
N/A | $55.0m | Post IPO Equity | |
* | N/A | $130m | Private Placement VC |
* | N/A | $6.7m | Post IPO Equity |
* | N/A | $60.0m | Post IPO Equity |
Total Funding | €123m |
Related Content
Recent News about Rezolute
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.